Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is in a strong position for growth with its diverse portfolio of generics, innovative medicines, and biosimilars in the neurology and immunology areas. With a solid presence in key markets such as North America and Europe, as well as potential for growth in emerging markets, the company has a strong foundation for long-term success. The recent acquisition of Emalex and the potential for a first-in-class D1 antagonist drug for the treatment of pediatric Tourette syndrome provide further potential for significant growth in the future. With continued focus on strategic BD and efficient allocation of capital, Teva has the potential to achieve significant revenue and profitability growth.

Bears say

Teva Pharmaceutical Indus is facing challenges in its generic drug business, as competition increases in the US market and the company faces patent expirations. The company's innovative portfolio and latest acquisition provide potential for growth, but execution remains crucial. While management is focused on cost savings and debt paydown to improve cash flows, there may be limited flexibility for large BD/M&A deals. Additionally, the recent court ruling on ProAir HFA patents could lead to competition for Teva's respiratory drugs, impacting sales.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Aug 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.